|
DK1537114T3
(da)
|
2002-08-07 |
2006-11-13 |
Novartis Ag |
Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
|
|
US20070004736A1
(en)
|
2002-11-22 |
2007-01-04 |
Keiji Kubo |
Imidazole derivative, process for producing the same, and use
|
|
MX2008015008A
(es)
|
2006-05-26 |
2008-12-05 |
Novartis Ag |
INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
|
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
|
WO2008078291A1
(en)
|
2006-12-22 |
2008-07-03 |
Actelion Pharmaceuticals Ltd |
5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
|
|
CN101686989B
(zh)
|
2007-06-21 |
2016-10-19 |
卡拉治疗学股份有限公司 |
取代的咪唑并杂环
|
|
US8859538B2
(en)
|
2007-06-21 |
2014-10-14 |
Cara Therapeutics, Inc. |
Uses of substituted imidazoheterocycles
|
|
CN101417999A
(zh)
|
2007-10-25 |
2009-04-29 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
|
CN101468988A
(zh)
|
2007-12-26 |
2009-07-01 |
上海恒瑞医药有限公司 |
哌嗪类衍生物,其制备方法及其在医药上的应用
|
|
CN102076694A
(zh)
|
2008-06-25 |
2011-05-25 |
埃科特莱茵药品有限公司 |
5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
|
|
WO2011092120A1
(en)
|
2010-01-29 |
2011-08-04 |
Nerviano Medical Sciences S.R.L. |
6,7- dihydroimidazo [1,5-a] pyrazin-8 (5h) - one derivatives as protein kinase modulators
|
|
CN102372716A
(zh)
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
US9145418B2
(en)
|
2011-10-07 |
2015-09-29 |
Nerviano Medical Sciences S.R.L. |
Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
|
|
CN103087067A
(zh)
|
2012-08-02 |
2013-05-08 |
盛世泰科生物医药技术(苏州)有限公司 |
作为二肽基酶抑制剂的化合物及其组合物，以及它们的用途
|
|
US9695176B2
(en)
|
2012-10-18 |
2017-07-04 |
Bristol-Myers Squibb Company |
Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists
|
|
US20160113893A1
(en)
|
2013-06-12 |
2016-04-28 |
Proximagen Limited |
New therapeutic uses of enzyme inhibitors
|
|
JP6820254B2
(ja)
|
2014-10-10 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
EP3632915A1
(en)
*
|
2014-11-27 |
2020-04-08 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
|
GB201506658D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
GB201506660D0
(en)
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
EP3445750A4
(en)
|
2016-04-18 |
2019-11-27 |
Celgene Quanticel Research, Inc. |
THERAPEUTIC COMPOUNDS
|
|
JP7014736B2
(ja)
|
2016-05-24 |
2022-02-01 |
ジェネンテック， インコーポレイテッド |
がんの処置のためのピラゾロピリジン誘導体
|
|
EP3464270B1
(en)
|
2016-05-24 |
2022-02-23 |
Genentech, Inc. |
Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
|
|
RU2020131507A
(ru)
|
2018-03-29 |
2022-05-04 |
Боард Оф Реджентс, Де Юниверсити Оф Техас Систем |
Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
|
|
WO2019195846A1
(en)
|
2018-04-06 |
2019-10-10 |
Board Of Regents, The University Of Texas System |
Imidazopiperazinone inhibitors of transcription activating proteins
|
|
CA3193745A1
(en)
|
2020-10-02 |
2022-04-07 |
Kang Le |
Imidazopiperazine inhibitors of transcription activating proteins
|
|
EP4221708A4
(en)
|
2020-10-02 |
2024-11-06 |
Board of Regents, The University of Texas System |
IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS
|